Pharma News

Pro sports’ COVID protocols led to real-world data impacts for pharma

This audio is auto-generated. Please let us know if you have feedback.

When Christina Mack was a junior in high school, she took an advanced placement computer science class because she was “just into it.” The only problem? It wasn’t offered at her all girls-school, so she had to make a daily trek to the all-boys school in her town. That was the early 1990s.

“Obviously, I was the only girl in the class, and they didn’t even offer it at my all-girls high school,” she said. “That kind of tells you where I’ve been.”

Professional headshot of Christina Mack

Optional Caption

Permission granted by Christina Mack


The class helped spark Mack’s love for “all things technical,” but it wasn’t until her first job out of college — she graduated with an engineering degree from the University of Notre Dame — in information technology as part of Johnson & Johnson’s leadership program that she realized data could “change the world.”

“It was like a fire was lit when I discovered you can apply the deep technology to healthcare and really make a difference for patients,” she said.

Now, after over two decades pioneering the use of technology and data science to revolutionize epidemiology — including through work with major league sports during the COVID-19 pandemic — Mack is hoping to push the field toward deeper patient insights as chief scientific officer for IQVIA’s real-world solutions business.

The role is perfectly suited for Mack, whose career has closely aligned with the rise of tech in the life sciences, often putting her at the forefront of major industry changes.

“It’s funny because when I decided to go get my Ph.D. in epidemiology, at that time, it was about 2008, people were like ‘Oh, you’re having a career change. You’re an engineer, you’re in technology, and now you’re going into healthcare” she said. “Now, those disciplines are not separate at all.”

And after years of timid acceptance, she believes the time is finally ripe for greater adoption of a major focus of her work: real-world data (RWD) across the life sciences industry.

“The data is richer than it was 10 years ago because we have people that have wearables, have people that are interacting with the healthcare system, and that information is going into the electronic health records,” Mack, who took over the IQVIA role from her longtime mentor and PharmaVoice 100 honoree Dr. Nancy Dreyer in June, said. “We now have the ability to put clinical outcome assessments to patients and understand from the patient’s perspective what matters to them.”

A data revolution

Mack partially credits her career success to having the right skillset at the right time.

She entered the life sciences industry at the dawn of the new millennium when Y2K fears were real, computer programmers were highly in-demand and pharma companies were figuring out how to electronically submit clinical trial documents to the FDA.

While she acknowledges it wasn’t the most glamourous job, creating the encryption codes for those electronic records enthralled Mack.

“I was just sold on working in healthcare from then on and I ended up moving to Africa and doing global health work. I did a whole lot of HIV (and) AIDS research and collecting information for healthcare in resource-constrained settings,” she said.

Eventually, that led her in 2007 to a first-of-its-kind project aimed at creating a global registry of avian flu cases. The research group she worked with, which also counted Dreyer among its ranks, collected and streamlined data from over 12 countries with outbreaks of the virus, each with different infrastructures for reporting cases, symptoms and outcomes.

“What happened with COVID, and especially in the sport setting, is that we were forced to do real public health in a way that we really hadn’t been forced to do in a long time.”

Christina Mack

Chief scientific officer, real-world solutions, IQVIA

“All of the techniques and frameworks we have for harmonizing data were either in their infancy or just didn’t exist,” Mack said. “And so, the processes that we had to put in place to get those cases and that data, and then understand the impact to patients, and whether that indication worked for that product, was just a really different model.”

Ultimately, the reporting system and agile analytics model they developed laid the groundwork that allowed scientists to understand the COVID-19 virus more quickly a decade later — a feat Mack also played a significant role in. In fact, her real-world research with both the National Football League (NFL) and National Basketball Association (NBA) led to pivotal discoveries about COVID-19 transmission, mitigation and vaccine effectiveness.

Source link
#Pro #sports #COVID #protocols #led #realworld #data #impacts #pharma

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *